<DOC>
	<DOCNO>NCT02367885</DOCNO>
	<brief_summary>The purpose study evaluate safety immunogenicity intramuscular injection TAK-850 healthy pediatric Japanese participant .</brief_summary>
	<brief_title>Phase 1/2 Study TAK-850 Intramuscular Injection Healthy Pediatric Participants</brief_title>
	<detailed_description>The drug test study call TAK-850 , development vaccine influenza infection . This study evaluate safety immunogenicity TAK-850 healthy Japanese child give intramuscular injection . The study enroll approximately 99 participant ( 33 per treatment group ) receive TAK-850 open label fashion , The participant assign treatment group follow : - single intramuscular injection TAK-850/0.5 mL 13 19 year old healthy Japanese child , - Two injection TAK-850/0.5 mL 3 12 year old healthy Japanese child , - Two injection TAK-850/0.25 mL 6 35 month old healthy Japanese child . The overall time participate trial 22 day ( 13-19 year old ) 43 day ( 6 month 12 year old ) . Participants make 2 visit ( 13-19 year old ) 3 visit ( 6 month 12 year old ) site .</detailed_description>
	<criteria>1 . In opinion investigator subinvestigator , participant and/or his/her representative his/her guardian capable understand comply protocol requirement . 2 . The participant 's representative sign date write , informed consent form prior initiation study procedure . 3 . The participant healthy Japanese child . 4 . The participant age 6 month 19 year , inclusive , time start receive study vaccine . 5 . A female participant childbearing potential sexually active nonsterilized male partner agree routinely use adequate contraception signing inform consent 12 week administration . [ Only participant age 635 month old ] 1 . The participant preterm newborn ( gestational age le 37 week ) lowbirthweight newborn ( birth weight less 2500 g ) . 2 . The participant receive investigational compound within 4 month prior initial injection study vaccine . 3 . The participant vaccinate seasonal influenza vaccine within 6 month prior initial injection study vaccine . 4 . The participant history influenza infection within 6 month prior initial injection study vaccine . 5 . The participant study site employee , immediate family member employee , dependent relationship study site employee involve conduct study ( e.g. , spouse , parent , child , sibling ) , may consent duress . 6 . The participant uncontrolled , clinically significant manifestation neurological , cardiovascular , pulmonary , hepatic , renal , metabolic , gastrointestinal , endocrine disorder , may impact ability participant participate potentially confound study result . 7 . The participant armpit temperature ≥ 37.5°C prior initial injection study vaccine Day 1 . 8 . The participant medically diagnose suspect immune deficient condition . 9 . The participant immune compromise condition disease , currently undergo form treatment undergoing form treatment expect influence immune response within 30 day prior initial injection study vaccine . Such treatment include , limited , systemic high dose inhale corticosteroid ( &gt; 800 μg/day beclomethasone dipropionate equivalent ; use inhale nasal steroid exceed level permit ) , radiation treatment immunosuppressive cytotoxic drug . 10 . The participant receive antipyretic within 4 hour prior initial injection study vaccine . 11 . The participant history GuillainBarré Syndrome , demyelinate disorder ( include acute disseminate encephalomyelitis [ ADEM ] multiple sclerosis ) convulsion . 12 . The participant functional surgical asplenia . 13 . The participant rash , dermatologic condition tattoo may interfere evaluation injection site reaction determine Investigator . 14 . The participant history , infect Hepatitis B Virus ( HBsAgs ) , Hepatitis C Virus ( HCV ) Human Immunodeficiency Virus ( HIV ) . 15 . The participant know hypersensitivity component TAK850 . 16 . The participant history severe allergic reaction anaphylaxis . 17 . The participant history drug abuse ( define illicit drug use ) history alcohol abuse within 1 year prior initial injection study vaccine unwilling agree abstain alcohol drug throughout study . 18 . The participant receive blood product ( e.g . blood transfusion immunoglobulin ) within 90 day prior initial injection study vaccine . 19 . The participant receive live vaccine within 4 week ( 28 day ) inactivate vaccine within 2 week ( 14 day ) prior initial injection study vaccine . 20 . If female , participant pregnant lactate intend become pregnant signing informed consent , , within 1 month participate study ; intend donate ova time period . 21 . The participant donate whole blood ≥ 200 mL within 4 week ( 28 day ) , ≥ 400 mL within 12 week ( 84 day ) , ≥ 800 mL within 52 week ( 364 day ) , blood component within 2 week ( 14 day ) prior initial injection study vaccine . 22 . In opinion investigator subinvestigator , participant unlikely comply protocol requirement consider ineligible reason .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Prevention</keyword>
</DOC>